National feature spotlights TumorSight™ Viz’s clinical use at Mercy Cedar Rapids and initiative with NVIDIA advancing AI-powered precision breast cancer care CHICAGO, IL – October 27, 2025 – SimBioSys®, an AI-driven precision medicine company revolutionizing how cancer is understood and…
By Stacey Stevens, President & CEO, SimBioSys Every October, pink ribbons remind us of how far we’ve come in the fight against breast cancer — and how far we still have to go. Despite remarkable progress in awareness, screening, and…
Commercial partnership expected to accelerate adoption of SimBioSys’ AI-powered surgical visualization platform following recent FDA clearance of TumorSight Viz 1.3 CHICAGO, IL and EXTON, PA, August 27, 2025 – SimBioSys®, a clinical AI company leveraging spatial biophysics to drive precision…
Latest release introduces industry-leading AI performance, optimized workflow integration, and enhanced surgeon usability to streamline imaging-to-intervention planning CHICAGO, July 9, 2025 /PRNewswire/ — SimBioSys®, a clinical AI company leveraging spatial biophysics to drive precision in breast cancer treatment, today announced its third…
Our presence at ASBrS will be an excellent opportunity to demonstrate how this synergy has the potential to benefit surgeons and patients by providing a clearer understanding of complex cancer surgeries before the first incision is made. EXTON, Pa. &…
PhenoScope™, SimBioSys’ powerful proprietary technology and service, can analyze vast fields of multi-modal data seamlessly, generating novel insights, including unique spatial biophysical insights in a 4-dimension space, for cancer drug discovery and development which are not apparent by looking at…
Metabolic reprogramming and tumor angiogenesis are two tightly linked hallmarks of cancer. Regions of high metabolic activity within a tumor can become hypoxic or nutrient starved, eliciting a cascade of pro-angiogenic signals that can lead to increased tumor perfusion and in turn greater metabolic…
As new antibody drug conjugates are developed, the question of which specific patients will respond to these therapies remains. This work develops a spatial PK/PD model for the antibody drug conjugate trastuzumab emtansine, T-DM1, and explores the relationship between HER2 (target) expression and other individual features of the tumor microenvironment…
The ESMO Breast Cancer 2022 took place in Berlin on May 3 – 5. A well-attended conference covering a broad range of breast cancer topics. Our team was there to present three posters. Here are our takeaway messages from the…
We developed an ensembled suite of convolutional neural networks (core components of SimBioSys TumorSight) that segmented tumor and other tissues, in and around the breast (chest, adipose, gland, vasculature, skin). We sought to validate model results against the expertise of…
SOLUTIONS
- TumorSight Viz
- TumorSight RISK
- PhenoScope
RESOURCES
©SimBioSys